Ocular infections:
Indications for: VIGAMOX
Susceptible bacterial conjunctivitis.
Clinical Trials:
In 2 randomized controlled trials, Vigamox produced clinical cures on day 5-6 in 66-69% of patients with bacterial conjunctivitis; microbiological success rates (eradication of baseline pathogens) ranged from 84-94%.
Vigamox was evaluated in a randomized, double-masked, parallel group study of pediatric patients with bacterial conjunctivitis between birth and 31 days of age. Patients were randomly assigned to receive Vigamox or another anti-infective agent. At day 9, results showed a clinical cure rate of 80% and a microbiological eradication success rate of 92%.
Adults and Children:
Instill 1 drop 3 times daily for 7 days.
VIGAMOX Warnings/Precautions:
For topical ophthalmic use only. Discontinue if superinfection or hypersensitivity occurs. Avoid contact lenses if symptomatic. Pregnancy. Nursing mothers.
VIGAMOX Classification:
Quinolone.
Adverse Reactions:
Conjunctivitis, decreased visual acuity, dry eye, keratitis, ocular discomfort, hyperemia, pain, pruritus, subconjunctival hemorrhage, tearing.
Drug Elimination:
Half-life: 13 hours.
How Supplied:
Soln—3mL
